Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Eye cancer, intraocular melanoma
Stage/Subtype:  iris melanoma
Trial Type:  Treatment
Results 1-10 of 10 for your search:
Start Over
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Any age
Trial IDs: 05-122, NCI-2016-00874, MSKCC-05122, NCT00445965
Yttrium Y 90 Resin Microspheres in Treating Patients With Uveal Melanoma Who Have Liver Metastases
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10C.95, NCI-2012-00140, 2010-02, NCT01473004
Nivolumab and Ipilimumab in Treating Patients with Metastatic Uveal Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0919, NCI-2015-00853, NCI-2012-00665, NCT01585194
Combination Chemotherapy and Tumor Infiltrating Lymphocytes with or without High Dose Aldesleukin in Treating Patients with Metastatic Ocular Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 13-C-0093, NCI-2013-01586, 130093, P131209, NCT01814046
Trametinib with or without GSK2141795 in Treating Patients with Metastatic Uveal Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9445, NCI-2013-02091, 13-144, NCT01979523
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13P.377, NCI-2014-00338, 2013-047, NCT02068586
Crizotinib following Surgery or Radiation Therapy in Treating Patients with High-Risk Uveal Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-063, NCI-2014-01895, NCI-2015-00689, NCT02223819
Pembrolizumab in Treating Patients with Advanced Uveal Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC MEL 1486, NCI-2015-00020, MEL1486, NCT02359851
Glembatumumab Vedotin in Treating Patients with Metastatic or Locally Recurrent Uveal Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9855, NCI-2015-00159, NCT02363283
Nivolumab with or without Ipilimumab before Surgery in Treating Patients with Stage IIIB-IV Melanoma That Can Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0041, NCI-2015-01520, NCT02519322
Start Over